VKH
CNCE

Virtu KCG Holdings’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Virtu KCG Holdings’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-66,897
Closed -$1.14M – 3642
2017
Q1 		$1.14M Buy
+66,897
New +$802K 0.03% 617
2015
Q3 		– Sell
-18,935
Closed -$282K – 3950
2015
Q2 		$282K Buy
+18,935
New +$288K 0.01% 2150

Other funds holding CNCE

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM

Virtu KCG Holdings's CNCE Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2017, closing a stake of 66,897 shares — an estimated $1.14M sold.

Virtu KCG Holdings first reported a position in CNCE in Q2 2015 and held it in 2 quarters. The position peaked at $1.14M in Q1 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 66,897 Concert Pharmaceuticals, Inc. shares in Q2 2017, an estimated $1.14M.
  • Virtu KCG Holdings first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 2 quarters.
  • Virtu KCG Holdings's Concert Pharmaceuticals, Inc. position peaked at $1.14M in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.